OR WAIT null SECS
Leading UK Research Center Adopts Medidata Technology Platform to Accelerate Clinical Research Across Portfolio and Its Translation Into Marketable Therapies. Initial Trials to Focus on Asthma and Bladder Cancer.
NEW YORK, N.Y. – Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences, and the Southampton Clinical Trials Unit at the University of Southampton today announced a partnership to accelerate drug development across the United Kingdom. Southampton’s Clinical Trials Unit (SCTU), part of the UK Clinical Research Collaboration, will leverage the Medidata Clinical Cloud to conduct more complex and scientifically rigorous clinical research. Funded by Cancer Research UK and the National Institute for Health Research (NIHR), SCTU’s portfolio consists of a diverse set of clinical development programs, including early-phase industry collaborations; multi-arm, multi-stage phase II and phase III trials; large pragmatic trials and stratified medicine program trials. SCTU is using Medidata’s technology platform to generate high-quality, standardized data that industry partners can use to support late-stage development programs and drug approval submissions in the UK and US. “At the Southampton Clinical Trials Unit, University of Southampton, we pride ourselves on working with the most skilled, experienced partners, investigators and sites to conduct high-quality, efficient trials. This new development could lead to more impactful clinical results that will potentially benefit the future treatment of patients in the UK and further afield,” said Professor Gareth Griffiths, director of the Southampton CTU. “With Medidata’s cutting-edge technology and off-the-shelf integration, we will be able to take on more complex and efficient studies, finding evidence of benefit in an academic research environment which could help industry by shortening their drug commercialization cycles and complementing other innovative work.” The University is implementing Medidata’s cloud-based technology for electronic data capture, management and reporting (Medidata Rave), clinical trial management (Medidata CTMS) and medical coding (Medidata Coder), enabling the SCTU to streamline clinical trials across all therapeutic areas, including oncology, respiratory, critical care and psychology. The first two studies leveraging the Medidata Clinical Cloud will focus on asthma and bladder cancer. “Southampton’s Clinical Trials Unit is well known across the UK for its expertise in the design, conduct and analysis of complex clinical trials,” said Christian Hebenstreit, Medidata’s managing director of EMEA. “Medidata is delighted to partner with the University to drive further innovation and efficiencies across Southampton’s research portfolio, while strengthening collaborations between academia and industry. Working together, we can expedite the research, discovery and development process to deliver promising new candidates to patients sooner.”
About University of Southampton
Through world-leading research and enterprise activities, the University of Southampton connects with businesses to create real-world solutions to global issues. Through its educational offering, it works with partners around the world to offer relevant, flexible education, which trains students for jobs not even thought of. This connectivity is what sets Southampton apart from the rest; we make connections and change the world.
is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. We are committed to advancing the competitive and scientific goals of our life sciences customers worldwide: more than 600 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations. Our industry-leading technology platform, the Medidata Clinical Cloud, is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, bringing new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting.